High-Throughput and Modular Solutions for Protein Therapeutics Discovery & Development
Therapeutic proteins have proven to be useful tools not only in cancer immunotherapies but also as promising treatment options for infectious diseases like COVID-19. Among some already licensed monoclonal antibodies (mAbs), several new developments (or molecule types) like next generation antibodies (bispecific, nanobodies, antibody fragments and antibody drug conjugates (ADCs) are in pre- clinical and clinical trials to investigate whether they can effectively treat different types of cancers and other diseases.
To mount a successful mAb, nanobody, bispecific antibody or antibody fragment discovery and development program to address difficult target classes, you need the latest technologies that allow rapid identification and characterization of candidate molecules to identify those with superior target reactivity and to further optimize their functionality.
Our innovative solutions for discovery and development of protein therapies streamline the workflow and increase productivity.
Accelerate your biotherapeutic development and still have peace of mind.
Find Resources View Article Collection
Ensure confidence in your biotherapeutic discovery and development program:
Product Highlights for Protein Therapeutics Discovery & Development
Cell Analysis Platforms
CellCelector Automated Cell Imaging and Picking System
Fully automated cell imaging and picking system developed for screening, selection and isolation of single cells, clusters, spheroids, and organoids as well as single cell clones and adherent colonies.
Incucyte® Live-Cell Analysis System
Enables real-time, live-cell imaging and analysis directly inside your incubator. Measure kinetic effects of your antibody treatment on target cells without ever having to remove cells from the incubator.
iQue® 3 High-Throughput Cytometry Platform
High-throughput, suspension cell and bead analysis platform for rapidly profiling of cell phenotype and function in therapeutic antibody discovery workflows. Ideal for those screens where cells are precious or limited in number, the iQue® 3 is the fastest way to generate high-content data from small samples.
Protein Analysis Platforms
Octet® Label-Free Bio-Layer Interferometry (BLI) Detection Systems
Octet® systems are used for affinity ranking, epitope binning of small to large antibody matrices, Fc-receptor binding, cross-reactivity testing of other species, glycosylation screening, characterization of antibody-antigen binding kinetics and affinity, bispecific testing, and titer analysis for protein expression, all in one high throughput, easy-to-use system.
Octet® SF3 Surface Plasmon Resonance (SPR)
With exceptional sensitivity for both small and large molecules, the Octet® SF3 allows users to generate high-quality kinetics and affinity data in a fraction of the time compared to standard multi-cycle kinetics.
Solutions for Downstream Applications
mAb Purification Mini Platform
Sartorius’s mAb purification mini platform is ideal for small-scale purification of your mAb from up to 1 L of cell culture supernatant.
The mini platform includes up to seven steps to take you through all the workflows necessary for mAb purification: cell clarification and filtration, antibody capture by affinity chromatography, purification step(s), concentration, and sterile filtration.
Each of our application steps maximizes output for the next step in the workflow, to support a seamless mAb purification process with maximum output.
Additional Solutions
Cell Line Development: A Perfect Fit, From Start to Finish
Cell line development with intelligent tools, services, and solutions for your unique needs.
Umetrics® Suite for Advanced Data Analytics
Accelerate drug development by using Design of Experiment (DOE) to efficiently plan your experiments and analyze your results with MODDE®.
Automated Single Plasma B-Cell Secretion Screening and Recovery
Identification and selection of optimal clones that secrete high levels of the desired antibody is one of the critical and time-consuming steps in the antibody discovery process.
